Prof
Jan Verhoef PhD MD, ChairmanThe scientific advisory board of AM-Pharma currently consists of the following individuals:
Prof
Jan Verhoef PhD MD, ChairmanProf Jan Verhoef is Chairman of the Eijkman-Winkler Institute of Microbiology, Infectious Diseases and Inflammation at the University Medical Centre Utrecht, and Co-ordinator of the European Network of Antimicrobial Resistance and Epidemiology (ENARE) Study. He graduated and received his PhD in microbiology at Utrecht University. His postgraduate training took place at the University of Minnesota, and at the Public Health Laboratory in Manchester, UK.
Prof Verhoef started his research career as Assistant Professor of Clinical Bacteriology at the Free University of Amsterdam, and then at the University of Utrecht. He was a Visiting Assistant Professor of Medicine at the University of Minnesota in Minneapolis and, afterwards, became Professor of Clinical Microbiology at the University of Utrecht. He was also a Visiting Professor of Medicine at Stanford University Medical Centre, Palo Alto Medical Foundation Research Institute, and was appointed by Royal Decree as a member of the Governmental Advisory Board for the Registration of Drugs, on which he served seven years.
Prof Verhoef is an active member of numerous professional societies, including the British Society for Antimicrobial Chemotherapy, the American Society for Microbiology, and the European Society for Clinical Microbiology Infectious Diseases. He is honorary member of both the Spanish Society of Medical Microbiology and the Slovak Society of Chemotherapy. He was the first president of the ESCMID and served as past-presidents of the International Immunocompromised Host Society and the Dutch Society for Microbiology. He has (co-)authored more than 500 scientific publications, journals and books, and is also a member of the editorial boards of a number of medical journals.
Prof
Michael Zasloff MD PhDProf Zasloff is the founding scientist of Genaera (formerly Magainin Pharmaceuticals, Inc.), President of the Magainin Research Institute and served as Executive Vice President and Vice Chairman of the company until mid 2001. He is regarded as a pioneer in the discovery and development of antimicrobial peptides and has published over 100 articles and holds over 30 US patents in this area. Prior to founding Magainin Pharmaceuticals, Prof Zasloff was the Charles E.H. Upham Professor of Pediatrics at the University of Pennsylvania School of Medicine and Director of the Division of Human Genetics and Molecular Biology, Children’s Hospital of Philadelphia. In the 1980s Prof Zasloff was Chief of Human Genetics of the National Institute of Child Health and Human Development of the National Institutes of Health. Prof Zasloff received an MD and a PhD from New York University School of Medicine in 1973. In January 2002, Prof Zasloff was appointed Dean of Research and Translational Science at Georgetown University School of Medicine (Washington, DC).
Prof
Dr Jean-Louis Vincent MD PhD Prof Jean-Louis Vincent obtained his MD with magna cum laude in 1973 from the Free University of Brussels. He became fully specialized in internal medicine in 1978. In 1982, Prof Vincent obtained his PhD at the Uni¬versity of Brussels and is currently Head of the Department of Intensive Care at the Erasme University Hospital in Brussels. His main fields of investiga¬tions include severe sepsis, acute circulatory failure and its treatment, oxygen transport, sepsis, hemodynamic monitoring and vital emergen¬cies. For 22 years he has organized an International Symposium on Intensive Care and Emergency Medicine, which is held every March in Brussels. This symposium, which gathers more than 4,000 participants, has become one of the largest meetings in the field. Prof Vincent has published more than 440 original articles and 60 books.
Prof
John C Marshall PhDProf John C. Marshall is a Professor of Surgery at the University of Toronto and an attending critical care surgeon at the Toronto General Hospital. He splits his clinical activities between abdominal surgery and surgical infections and critical care and is the Director of Research for the Critical Care Medicine Programme of the University of Toronto. Prof Marshall’s academic interests are sepsis and the systemic inflammatory response. He has a CIHR funded laboratory whose focus is the regulation of neutrophil mediated inflammation. In addition he has been actively involved in the design and conduct of clinical trials in sepsis, serving as an advisor to a number of pharmaceutical companies undertaking research in this area. He has published more than 120 peer-reviewed papers and 55 book chapters and is the editor of two books.
Prof
Sander van Deventer MD PhDProf Sander van Deventer is professor in Experimental Medicine at the University of Amsterdam Medical School, the Netherlands. He also is the co-founder and CSO of Amsterdam Molecular Therapeutics B.V., and venture partner with ABNAMRO Life Sciences. Prof van Deventer received his medical degree and doctor of philosophy from the University of Amsterdam. Board certified in internal medicine and gastroenterology, he has been a member of advisory boards of the Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products, and a consultant for a significant number of companies, both biotech and large pharma. Prof van Deventer is the author of numerous articles and book chapters on infectious diseases, inflammatory bowel disease and colorectal cancer.
Prof
Klaas Poelstra PhDProf Klaas Poelstra, received his PhD in Medical Biology in 1992 (cum laude). He has a strong scientific background focussing on the design of novel anti-inflammatory proteins and on drug targeting strategies. He is inventor of many compounds under development in several Biotech start-ups, such as alkaline phosphatase (AM-Pharma BV) and protein-based drug carriers (BiOrion Technologies BV). Prof Poelstra is since 2004 adjunct-professor in Drug Targeting at the University of Groningen. He was honoured for the "NWO Vernieuwingsimpuls 2000" and received the
